生命科学资讯

Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist | PharmExec - Pharmaceutical Executive

Roche, trailing in obesity, showcases new data for GLP-1 shot

How Roche is Scaling Production After Obesity Breakthrough - Manufacturing Digital Magazine

Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial - Fierce Biotech

Roche announces positive phase II results for experimental obesity drug - wkzo.com

Roche's Gazyva gets Health Canada approval for lupus nephritis - marketscreener.com

Roche boosts NC factory investment to $2B; Rentschler CEO steps down

Anthropic, Roche & NVIDIA: This Week's Top Stories - Healthcare Digital

Roche: Making Preventative Healthcare Accessible to All - Healthcare Digital

Chutes & Ladders—Former Roche oncology head turns to Tubulis

Former Roche oncology head turns to Tubulis—Chutes & Ladders - fiercebiotech.com

Roche returns to Chinese biotech MediLink for another ADC pact

Roche returns to Chinese biotech MediLink for another ADC pact - Endpoints News

Roche divulges new NLRP3 inflammasome inhibitors

Roche returns to MediLink with promise of $570M near-term payments for another ADC

Roche returns to MediLink with $570M near-term payments for ADC - Fierce Biotech

Ollin’s drug clears retinal disease better than Roche’s Vabysmo in Phase 1b trial

Charles Fuchs leaves Roche to steer ADC pipeline at Tubulis shortly after $401M Series C

In Structure licensing deal, Roche commits $100M to shore up GLP-1 position

In Structure licensing deal, Roche commits $100M to shore up GLP-1 position - Fierce Biotech